benefit of retatrutide Buy in the UK This weight-loss drug hasn't been

A phase 2 trial of Retatrutide (TripleHormone-Receptor Agonist) for obesity

N = 161,798 after matching GLP-1RA vs diet/exercise consultation Median follow-up: 2 years Key result: Any obesity-associated cancer HR 0.59, 95% CI 0.53-0.67 Site-specific signals: Multiple myeloma HR 0.37 Pancreatic cancer HR 0.40 Endometrial cancer HR 0.42 Colorectal cancer HR 0.49 But remember: This is observational

Women on GLP-1 drugs had an 8% lower risk of obesity-related cancers and a 20% lower risk of death from any cause, compared to those taking #DPP4 inhibitors

Doctor-led weight care across India.

It is clinically studied and has shown an improvement in blood glucose, cholesterol and body composition over time and in addition to a healthy wellness routine